Lnc<scp>RNA SNHG</scp>4 promotes tumour growth by sponging miR‐224‐3p and predicts poor survival and recurrence in human osteosarcoma

Xu, Ruida; Feng, Fan; Yu, Xiaosheng; Liu, Zude; Lao, Li

doi:10.1111/cpr.12515

Cited by 106 publications

(101 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differential expression of a certain gene in patients and healthy participants indicated its involvement in diseases. In a recent study Xu et al reported that SNHG4 was downregulated in osteosarcoma and its overexpression promoted cancer cell proliferation and predicted the recurrence and poor survival of osteosarcoma patients [13]. In this study, we analyze TCGA dataset and observed the downregulation of SNHG4 in AML.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

LncRNA SNHG4 regulates miR-10a/PTEN to inhibit the proliferation of acute myeloid leukemia cells

Yuan¹,

Wang

2020

Hematology

View full text Add to dashboard Cite

Objectives: Long non-coding RNA (lncRNA) small nucleolar RNA host gene 4 (SNHG4) is a characterized oncogenic lncRNA in osteosarcoma. The analysis of the TCGA dataset suggested the downregulation of SNHG4 in acute myeloid leukemia (AML), indicating its possible involvement in this disease. Therefore, this study was performed to analyze the interaction between SNHG4 and miR-10a in AML. Methods: We included 60 patients with AML and 60 healthy participants. Transient transfections, luciferase activity assay, RT-qPCR, CCK-8, and Western blot were used to carry out the research. Results: In this study, we found that SNHG4 was downregulated in AML patients compared to healthy participants. SNHG4 and miR-10a can interact with each other. However, overexpression of SNHG4 and miR-10a failed to affect the expression of each other. Instead, SNHG4 overexpression led to upregulated PTEN, a downstream target of miR-10a. Cell proliferation analysis showed that SNHG4 and PTEN overexpression led to decreased proliferation rates of AML cells and attenuated the enhancing effects of miR-10a on cell proliferation. Conclusion: In conclusion, SNHG4 may regulate miR-10a/PTEN to inhibit the proliferation of AML cells.

show abstract

Section: Discussionmentioning

confidence: 78%

“…Accumulative evidence suggests that some miRNAs, such as miR-10a, can target PTEN to promote the development of cancer [12]. Small nucleolar RNA host gene 4 (SNHG4) is a recently characterized long non-coding RNA (lncRNA) in osteosarcoma [13]. By analyzing TCGA dataset, we observed the downregulation of SNHG4 in AML.…”

Section: Introductionmentioning

confidence: 92%

LncRNA SNHG4 regulates miR-10a/PTEN to inhibit the proliferation of acute myeloid leukemia cells

Yuan¹,

Wang

2020

Hematology

View full text Add to dashboard Cite

show abstract

“…Dysregulation of lncRNA MEG3 could act as a potential predictor of the progression and poor prognosis of osteosarcoma [10], and overexpression of lncRNAs UCA1 and TUG1 are essential in the poor prognosis of osteosarcoma [11,12]. In addition, SNHG4 promotes tumor growth and is a predictor of poor survival and recurrence in human osteosarcoma [13]. HNF1A-AS1 is a negative prognostic biomarker that promotes tumorigenesis and progression in osteosarcoma [14].…”

Section: Introductionmentioning

confidence: 99%

The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma

et al. 2020

View full text Add to dashboard Cite

Background: Osteosarcoma is the most common primary bone malignancy in children and adolescents. In order to find factors related to its recurrence, and thus improve recovery prospects, a powerful clinical signature is needed. Long noncoding RNAs (lncRNAs) are essential in osteosarcoma processes and development, and here we report significant lncRNAs to aid in earlier diagnosis of osteosarcoma. Methods: A univariate Cox proportional hazards regression analysis and a multivariate Cox regression analysis were used to analyze osteosarcoma patients’ lncRNA expression data from the Therapeutically Applicable Research To Generate Effective Treatments (TARGET), a public database. Results: A lncRNA signature consisting of three lncRNAs (RP1-261G23.7, RP11-69E11.4 and SATB2-AS1) was selected. The signature was used to sort patients into high-risk and low-risk groups with meaningful recurrence rates (median recurrence time 16.80 vs. >128.22 months, log-rank test, P<0.001) in the training group, and predictive ability was validated in a test dataset (median 16.32 vs. >143.80 months, log-rank test, P=0.006). A multivariate Cox regression analysis showed that the significant lncRNA was an independent prognostic factor for osteosarcoma patients. Functional analysis suggests that these lncRNAs were related to the PI3K-Akt signaling pathway, the Wnt signaling pathway, and the G-protein coupled receptor signaling pathway, all of which have various, important roles in osteosarcoma development. The significant 3-lncRNA set could be a novel prediction biomarker that could aid in treatment and also predict the likelihood of recurrence of osteosarcoma in patients.

show abstract

“…Recently, dysregulation of lncRNAs have been shown to be involved in carcinogenesis and tumour development and can be used as a cancer therapeutic or prognostic biomarker [21][22][23]. Currently, we observed that LINC-PINT expression in NSCLC tissues and cell lines were downregulated.…”

Section: Discussionmentioning

confidence: 77%

Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4

Zhang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Long noncoding RNA, long intergenic non-protein-coding RNA p53-induced transcript (LINC-PINT) was showed to be involved in cancer development. However, the biological effect of LINC-PINT on nonsmall cell lung cancer (NSCLC) remains unknown. Here, we aimed to investigate the role and underlying mechanism of LINC-PINT in NSCLC. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the level of LINC-PINT in NSCLC tissues and cell lines. Cell counting kit-8 (CCK-8), flow cytometry, migration and transwell invasion assays were used to investigate cell proliferation, cell cycle, cell migration and invasion, respectively. The targets of LINC-PINT were verified by both luciferase reporter assay and RNA immunoprecipitation assay. Tumour xenografts were used to reveal the effect of LINC-PINT on tumourigenesis in vivo. We observed that LINC-PINT expression increased in both NSCLC tissues and cell lines. Function assays exhibited that LINC-PINT reduced NSCLC cell proliferation, cell cycle, cell migration and invasion in vitro. We also indicated that LINC-PINT mediated inhibitory effect on cell proliferation, cell cycle, cell migration and invasion by miR-208a-3p/programmed cell death 4 (PDCD4) in NSCLC cells. These findings indicated that LINC-PINT functions as a tumour-suppressor that exerts important regulatory roles in NSCLC progression by sponging miR-208a-3p/PDCD4.

show abstract

LncRNA SNHG4 promotes tumour growth by sponging miR‐224‐3p and predicts poor survival and recurrence in human osteosarcoma

Abstract: Our findings demonstrated that LncRNA SNHG4 promoted tumour growth by sponging miR-224-3p and represented a poor prognostic factor in patients with osteosarcoma.

Cited by 106 publications

References 25 publications

LncRNA SNHG4 regulates miR-10a/PTEN to inhibit the proliferation of acute myeloid leukemia cells

LncRNA SNHG4 regulates miR-10a/PTEN to inhibit the proliferation of acute myeloid leukemia cells

The lncRNAs RP1-261G23.7, RP11-69E11.4 and SATB2-AS1 are a novel clinical signature for predicting recurrent osteosarcoma

Long noncoding RNA LINC-PINT inhibits non-small cell lung cancer progression through sponging miR-218-5p/PDCD4

Contact Info

Product

Resources

About